IRWD
Ironwood Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
IRWD fundamentals
Ironwood Pharmaceuticals (IRWD) released its earnings on Feb 25, 2026: revenue was 47.71M (YoY -47.31%), missed estimates; EPS was -0.01 (YoY -150.00%), beat estimates.
Revenue / YoY
47.71M
-47.31%
EPS / YoY
-0.01
-150.00%
Report date
Feb 25, 2026
IRWD Earnings Call Summary for Q4,2025
- LINZESS Revival: 2026 U.S. net sales expected to exceed $1.1 billion, up 30% YoY, driven by price adjustment and demand growth. 2025 ended with $250M cash, enabling debt reduction to $300M by year-end.
- Apraglutide Milestone: STARS-2 Phase III trial begins Q2 2026, targeting 124 patients with SBS-IF. FDA alignment on endpoints increases confidence in eventual NDA submission by 2029.
- Financial Discipline: 2025 operating expenses reduced by $61M, with 2026 adjusted EBITDA >$300M. Focus on deleveraging to 1x EBITDA while funding clinical trials.
- Market Leadership: LINZESS maintains 45% IBS-C/CC market share, with 5.7M unique patients treated. Apraglutide's once-weekly profile positions it as best-in-class against daily GLP-2 competitors.
Earnings
EPS
Revenue
Revenue & Expenses
IRWD has released its 2025 Q4 earnings report, with revenue of 47.71M, reflecting a YoY change of -47.31%, and net profit of -2.28M, showing a YoY change of -200.89%. The Sankey diagram below clearly presents IRWD's revenue sources and cost distribution.
Key Indicators
Ironwood Pharmaceuticals (IRWD) key financial stats and ratios, covering profitability, financial health, and leverage.
Income Statement
Ironwood Pharmaceuticals (IRWD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Balance Sheet
Ironwood Pharmaceuticals (IRWD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cash Flow
Ironwood Pharmaceuticals (IRWD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Revenue Breakdown
Where does Ironwood Pharmaceuticals (IRWD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Dividend
Track Ironwood Pharmaceuticals (IRWD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the market's earnings forecast for Ironwood Pharmaceuticals next quarter?What guidance did Ironwood Pharmaceuticals's management provide for the next earnings period?What is the revenue and EPS growth rate for Ironwood Pharmaceuticals year over year?What were the key takeaways from Ironwood Pharmaceuticals’s earnings call?What is Ironwood Pharmaceuticals's latest dividend and current dividend yield?What does Ironwood Pharmaceuticals do and what are its main business segments?What is Ironwood Pharmaceuticals's gross profit margin?Did Ironwood Pharmaceuticals beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
